| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Matinas Biopharma Holdings, Inc.$0.76
+0.13 (+20.46%)
D 24Pipeline Score Overvalued Pharma · Clinical
Market Cap
4.51 M
EPS
-2.02
P/E Ratio
-
Value Trade
72.89 K
SEC Financials
Q1 2026Dilution Risk
Operating CF
-1.60 M
Total Assets
5.87 M
Total Liabilities
2.85 M
Equity
3.02 M
D/E Ratio
12,345
24.62 %
Week
25.73 %
1 Month
12.34 %
3 Month
-18.98 %
6 Month
-98.28 %
5 Year
-98.59 %
All Time
Cash Data
Cash Position
2.40 M
Monthly Burn
534.00 K
Runway
2.6 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
1.69 M
52 Week Range
0.48 - 3.09
% held by Insiders
18.82 %
% held by Institutions
5.68 %
Enterprise Value
3.25 M
Total Shares
6.41 M
Short %
0.11 %
Float Shares
5.31 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Matinas Biopharma Holdings, Inc.
654Total events
1Upcoming
105Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 1
Event history 653
Jun 24, 2026
▼Going ConcernCorporate
Received notice of non-compliance with NYSE American continued listing standards
Apr 3, 2026
Apr 2, 2026
▼Restructuring LayoffsCorporate
Received NYSE American non-compliance notice for continued listing standards
Q2 2025
Mar 11, 2025
▲Management ChangeCorporate
Appointment of Keith Murphy and Edward Neugeboren to Board of Directors
Feb 13, 2025
▼Equity OfferingCorporate
Agreement for acquisition of Preferred Stock and warrants for $3.3 million gross proceeds
Feb 13, 2025
◆Management ChangeCorporate
Resignation and retirement of founding Chairman Herbert J. Conrad
Feb 13, 2025
◆Pipeline PrioritizationMAT2203ApprovedCorporate
Exploring strategic alternatives for MAT2203
invasive fungal infectionssource ↗
Jan 6, 2025
▼Quarterly UpdateCorporate
Received NYSE American noncompliance notice for failure to hold annual meeting
Oct 31, 2024
▼Partnership / LicenseMAT2203ApprovedCorporate
Termination of MAT2203 partnership negotiations
invasive fungal infectionssource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $1M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 23%
Micro Cap (rank 702 of 911)
Percentile RankMatinas Biopharma Holdings, Inc. faces pipeline headwinds (24/100), with $1.3B risk-adjusted pipeline value, led by icosapent ethyl in Hypertriglyceridemia (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| icosapent ethyl Small molecule | Hypertriglyceridemia | Phase 2 | NCT04177680 | 27% | $638M | COMPLETED | 100 | - | - | Jan 18, 2021 | - | Mar 4, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LNC-docetaxel | multiple metastatic and unresectable tumors | — | 2024-03-27 | no evidence of weight loss; average peak weight loss of 20% with IV-docetaxel; more than 8x greater than IV-docetaxel Read More | Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of wei Read More | |
LNC-docetaxel | multiple metastatic and unresectable tumors | — | 2024-03-27 | no evidence of weight loss; average peak weight loss of 20% with IV-docetaxel; more than 8x greater than IV-docetaxel Read More | Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of wei Read More | |
LNC-docetaxel | multiple metastatic and unresectable tumors | — | 2024-03-27 | no evidence of weight loss; average peak weight loss of 20% with IV-docetaxel; more than 8x greater than IV-docetaxel Read More | Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of wei Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MTNB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MTNB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MTNBMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma has received a notice from NYSE American regarding non-compliance with listing standards due to insufficient stockholders' equity. The company submitted a plan to regain compliance, which has been accepted, allowing it to continue trading while under review. However, the company has reported losses for five years, raising concerns about its financial stability.
Read more →MTNBMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Matinas BioPharma received a notice from NYSE American indicating non-compliance with continued listing standards due to insufficient stockholders' equity amid reported losses. The company has until May 2, 2026, to submit a plan to regain compliance, which, if accepted, would allow it to continue trading during a designated cure period. Should the plan be rejected, delisting proceedings may commence, although no immediate impacts on share trading have been noted. Additionally, concerns about the company's long-term viability have been raised by its independent auditors.
Read more →MTNBMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Matinas BioPharma has appointed Keith Murphy and Edward Neugeboren to its Board of Directors, effective March 11, 2025. The new members bring extensive experience in the biotech industry, with Murphy taking on the role of Chair of the Nominating and Governance Committee and Neugeboren becoming Chair of the Compensation Committee. The company expresses gratitude to departing directors Matthew Wikler and Natasha Giordano for their service.
Read more →MTNBMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
Matinas BioPharma has entered into a securities purchase agreement for the sale of 3,300 shares of Series C Convertible Preferred Stock, raising $3.3 million. The company appointed Dr. Robin L. Smith to its Board of Directors, enhancing its leadership. The funds will be used for corporate purposes, particularly to support the development of MAT2203, an antifungal drug candidate.
Read more →MTNB▲ +8.8%on this news
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
Matinas BioPharma has appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025. D'An has a strong background in financial oversight and corporate governance, having served in various capacities at public and private companies. Her expertise is expected to enhance the Board's effectiveness during a pivotal time for the company.
Read more →MTNBMatinas BioPharma Receives NYSE Noncompliance Notice
Matinas BioPharma Holdings, Inc. received a notice from NYSE American for not holding its annual stockholder meeting for the fiscal year ending December 31, 2024. The company plans to hold this meeting by December 31, 2025, to regain compliance. This situation raises concerns about its listing status and future operations.
Read more →MTNB▼ -67.9%on this news
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Matinas BioPharma has terminated its partnership negotiations for MAT2203, an oral antifungal treatment, leading to an 80% workforce reduction and the cessation of product development activities. Key executives, including the Chief Medical Officer and Chief Technology Officer, are among those affected by the layoffs. The company is evaluating the potential sale of MAT2203 but faces uncertainties regarding favorable sale conditions. Future developments may include winding down operations or dissolving the company altogether if conditions do not improve.
Read more →MTNBMatinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Holdings, Inc. has reported its financial results for the second quarter of 2024 alongside a business update. The company announced signing a non-binding term sheet granting global rights for its oral antifungal drug MAT2203, targeting invasive aspergillosis. Positive clinical outcomes have been noted in patients receiving MAT2203 under a Compassionate Use program. However, the company continues to experience net losses, and no revenue was reported for the second quarter.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Matinas BioPharma Holdings, Inc. will report its second quarter 2024 financial results on August 14, 2024. The company will also provide a business update during a conference call at 4:30 p.m. Eastern time. The conference call is accessible by phone and a webcast will be available on the company's website. Matinas focuses on innovative therapies using lipid nanocrystal delivery technology, with its lead therapy MAT2203 demonstrating significant potential in treating invasive fungal infections.
Read more →MTNB▲ +6.7%on this news
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Matinas BioPharma announced a successful case of treating a patient with a serious limb-threatening mucor infection using its oral formulation MAT2203. The 22-year-old patient was discharged after six weeks of treatment, having previously experienced severe adverse effects from intravenous amphotericin. The company highlights positive clinical outcomes and ongoing efforts to advance MAT2203 through further trials, including a Phase 3 study aimed at validating its efficacy against invasive fungal infections. MAT2203 is being developed due to its potential to deliver antifungal therapy with reduced toxicity compared to traditional options.
Read more →MTNBMatinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Matinas BioPharma's oral formulation MAT2203, aimed at treating invasive fungal infections, will be showcased in a fireside chat hosted by A.G.P., featuring Dr. David S. Perlin. The discussion will focus on the current antifungal market, MAT2203's clinical potential, and the design of the pivotal ORALTO trial. Previous studies indicate MAT2203's effectiveness in improving patient outcomes, positioning it as a promising treatment alternative. The event is scheduled for June 18, 2024.
Read more →MTNBMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma reported its financial results for Q1 2024, highlighting a net loss of $5.8 million and a significant decrease in cash reserves. The company raised $10 million through financing, intending to fund development programs into 2025. Notably, Matinas is actively pursuing partnerships to advance its MAT2203 therapy into Phase 3 trials for invasive aspergillosis. Positive in vivo results from studies suggest the potential of its lipid nanocrystal platform technology in broader treatment applications.
Read more →MTNBMatinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
Matinas BioPharma announced that its lipid nanocrystal (LNC) platform will be featured in two presentations at the ASGCT Annual Meeting. The presentations will showcase data from studies on the uptake and targeted delivery of small oligonucleotides, emphasizing LNC's ability to efficiently deliver therapeutic agents. Positive findings from both in vitro and in vivo studies support the platform's potential in treating inflammatory diseases. The company is also focused on optimizing LNC formulations to enhance delivery efficiency and increase therapeutic potency.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
Matinas BioPharma Holdings, Inc. announced that it will report its first quarter 2024 financial results on May 9, 2024, and host a conference call to update investors. The company is known for its lipid nanocrystal platform technology, which aims to improve antifungal treatment through its lead product, MAT2203. MAT2203 has shown efficacy in previous trials, providing a safer oral delivery method for antifungal agents. However, the company faces challenges, including the need for regulatory approvals and potential capital requirements for ongoing research and development.
Read more →MTNB▼ -35%on this news
Matinas BioPharma Prices $10 Million Registered Direct Offering
Matinas BioPharma has announced a registered direct offering, pricing 33,333,334 shares of common stock and associated warrants, aiming to raise approximately $10 million. The company intends to use these proceeds primarily for working capital and corporate purposes. The offering is expected to close on April 5, 2024, subject to customary conditions. Matinas BioPharma is known for its innovative lipid nanocrystal technology, which aims to enhance drug delivery and efficacy.
Read more →MTNB▼ -35%on this news
Matinas BioPharma Announces Registered Direct Offering of $10 Million BEDMINSTER, N.J.
Matinas BioPharma Holdings, Inc. announced a registered direct offering of $10 million through the sale of 33,333,334 shares of common stock and related warrants. The offering aims to support the company’s working capital and general corporate purposes, with closure expected by April 5, 2024. The company's lead candidate, MAT2203, has shown promise in prior clinical trials and will undergo further evaluation in a Phase 3 trial.
Read more →MTNBMatinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Matinas BioPharma reported its 2023 financial results while highlighting key advancements in the development of MAT2203, an oral treatment for invasive aspergillosis. The FDA has aligned with Matinas on the Phase 3 ORALTO trial design, which is crucial for the drug's potential commercialization. Additionally, the company's LNC platform demonstrates promising results in both oncology and inflammation treatments, further diversifying its therapeutic pipeline. Overall, Matinas is actively pursuing partnerships to expedite the advancement of MAT2203.
Read more →MTNBMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of wei
Matinas BioPharma has announced positive results from its in vivo study of an oral formulation of LNC-docetaxel, which administered a dose significantly greater than traditional IV-docetaxel without causing weight loss in mice. This could address the severe side effects typically associated with IV administration of docetaxel, including considerable weight loss. The study supports previous findings that demonstrate LNC-docetaxel's effectiveness in reducing tumor size. The company plans to explore higher doses and further therapeutic applications for this delivery system.
Read more →MTNBMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Matinas BioPharma announced positive results from an in vivo study of its oral LNC-docetaxel formulation, which demonstrated no weight loss in treated mice compared to significant weight loss with IV-docetaxel. The study supports prior findings showing effective tumor targeting and size reduction comparable to standard IV treatment without evident toxicity. This technology may offer an innovative method to reduce chemotherapy-associated side effects. Looking ahead, the company plans to evaluate the effectiveness of higher doses of oral LNC-docetaxel in additional tumor types and toxic chemotherapies.
Read more →MTNBThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response BEDMINSTER, N.J. (
Matinas BioPharma announced that three patients with serious invasive fusarium infections achieved complete clinical responses after being treated with MAT2203, their oral formulation of amphotericin B. This treatment was provided through the Compassionate/Expanded Use Access Program and has demonstrated potential benefits for patients with limited treatment options. As invasive fusarium species are often resistant to existing antifungals, the success of MAT2203 might represent a significant advancement in addressing this unmet medical need. The results contribute to the overall confidence for the upcoming Phase 3 ORALTO trial for invasive aspergillosis patients.
Read more →MTNBMatinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Matinas BioPharma Holdings, Inc. has announced that it has regained compliance with NYSE American continued listing standards as of March 21, 2024. This comes after the company demonstrated sustained price improvement of its common stock, allowing it to be removed from the NYSE American noncompliant issuers list. Matinas is focused on developing therapies using its lipid nanocrystal delivery technology, notably featuring MAT2203, an oral antifungal treatment that recently met primary endpoints in Phase 2 studies. The company is preparing for further clinical evaluations as it enhances its market position.
Read more →MTNB▲ +12.4%on this news
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
Matinas BioPharma has reported positive outcomes for its MAT2203 program, an oral formulation of amphotericin B, in treating 19 patients with severe fungal infections. Notably, all five patients who completed treatment showed complete resolution of their infections, while those who transitioned from previous renal-toxic treatments experienced recovery of kidney function. The findings indicate the drug's potential for improving treatment for patients facing serious complications due to limited options. However, some patients had to discontinue treatment due to unrelated health issues.
Read more →MTNBMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Matinas BioPharma has reached an agreement with the FDA regarding the ORALTO Phase 3 trial for MAT2203, aimed at treating invasive aspergillosis in patients with limited treatment options. This pivotal trial will assess the efficacy of an oral step-down treatment compared to standard care, primarily focusing on all-cause mortality. The trial is expected to enroll approximately 216 participants and commence in the second half of 2024. The design of this registration trial builds upon previous successful findings and precedents set in earlier studies.
Read more →MTNBMatinas BioPharma to Present at Biotech Showcase 2024
Matinas BioPharma will present an overview at the Biotech Showcase 2024 in San Francisco on January 9, 2024. The company focuses on utilizing its lipid nanocrystal platform for safe intracellular delivery of drugs. Its lead product, MAT2203, an oral formulation of amphotericin B, has shown promising results in clinical trials, positioning it as a potential breakthrough therapy for antifungal treatment. The company's innovative technology aims to address significant challenges in drug delivery and safety.
Read more →MTNB▲ +20.4%on this news
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
Matinas BioPharma has reported promising results from in vivo studies demonstrating effective oral delivery and biological activity of their LNC-formulated small oligonucleotides targeting inflammatory cytokines TNFα and IL-17A in animal models of acute colitis and psoriasis. Significant reductions in cytokine mRNA levels and improvements in disease activity scores were observed in both studies. The company plans to further explore the data to optimize these therapies for future applications. This development underscores the potential of Matinas' lipid nanocrystal technology for advancing anti-inflammatory treatments.
Read more →MTNBMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
Matinas BioPharma has received written feedback from the FDA regarding the Phase 3 study of MAT2203, moving the company closer to alignment with regulatory requirements. The company plans to meet with the FDA in early 2024 to finalize the study design, aiming to commence the trial soon afterward. Additionally, discussions around partnerships for MAT2203 are ongoing, reflecting potential opportunities for collaboration. Positive data from ongoing programs supports the company's belief in the drug's commercial potential and addresses significant unmet medical needs.
Read more →MTNB▼ -13.8%on this news· ran to -32% by day 3
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
Matinas BioPharma reported its third-quarter financial results while providing a business update on its MAT2203 program. The FDA has shown support for the Phase 3 study design targeting invasive aspergillosis. Positive outcomes from compassionate use cases and preclinical studies of oral LNC-docetaxel were also highlighted. However, the company reported no revenue during the quarter and a slight increase in net loss compared to the previous year.
Read more →MTNB▲ +27.2%on this newsshared move
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
Matinas BioPharma announced positive in vivo efficacy results for its oral lipid nanocrystal (LNC) formulation of docetaxel in a melanoma mouse model. The study showed significant reductions in tumor sizes comparable to traditional intravenous administration without associated toxicities. Matinas aims to explore further evaluations of this formulation in other tumor models and longer-term treatment regimens to confirm safety and efficacy. The results represent a promising advance in the administration of chemotherapeutics, reflecting the potential of the LNC delivery platform.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
Matinas BioPharma Holdings, Inc. will release its third quarter financial results and provide a business update during a conference call on November 8, 2023. The company is focused on its innovative lipid nanocrystal (LNC) platform technology which aims to redefine the delivery of nucleic acids and small molecules. The lead product, MAT2203, has shown promise in clinical trials, particularly for antifungal therapy. However, the company faces challenges, including securing additional capital and regulatory approval for its products.
Read more →MTNBMatinas BioPharma to Present at Two Investment Conferences in October 2023
Matinas BioPharma announced that CEO Jerome D. Jabbour will be presenting at two upcoming investment conferences in October 2023. The presentations will cover the company's advancements in intracellular delivery technologies, particularly their lipid nanocrystal platform and its lead therapy, MAT2203. The conferences are set to occur in Jupiter, Fla., and New York City, providing opportunities for engagement with institutional investors. The company's innovative approach aims to deliver therapies with reduced toxicity, enhancing patient treatment options.
Read more →MTNB▼ -6.6%on this newsshared move
Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
Matinas BioPharma will feature its oral formulation MAT2203, aimed at treating invasive fungal infections, in a pipeline presentation at IDWeek from October 11-15, 2023. Dr. Theresa Matkovits, the Chief Development Officer, will discuss the clinical evidence supporting MAT2203's ability to improve patient outcomes while minimizing the toxic effects associated with intravenous AMB. The presentation is part of an effort to highlight the drug’s development towards an ideal antifungal treatment, emphasizing its potential to transform how such infections are managed.
Read more →MTNBMatinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
Matinas BioPharma has received a deficiency letter from NYSE American due to non-compliance with listing standards, attributed to its common stock trading at low prices. The company is required to either achieve price improvements or conduct a reverse stock split by March 21, 2024, to remain listed. Though the deficiency letter doesn't result in immediate delisting, it signifies a risk to the company’s stock status if improvements are not made within the stipulated timeframe. The company is actively working on strategies to regain compliance.
Read more →MTNB▼ -5.3%on this news
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
Matinas BioPharma Holdings, Inc. will participate in the H.C. Wainwright 25th Annual Global Investment Conference scheduled for September 11-13, 2023. During this event, CEO Jerome D. Jabbour will hold meetings with institutional investors to discuss the company's activities and advancements. Matinas BioPharma is recognized for its lipid nanocrystal platform technology, with its lead product, MAT2203, showing promising results in clinical trials for treating severe fungal infections. Despite the positive outlook, challenges such as securing capital and navigating clinical trial uncertainties persist.
Read more →MTNBMatinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
Matinas BioPharma announced the publication of Phase 2 EnACT trial results for MAT2203 in the IDSA journal Clinical Infectious Diseases. The trial evaluated MAT2203, an oral formulation of amphotericin B, for treating cryptococcal meningitis in HIV-positive individuals. Results indicate that MAT2203 demonstrated promising antifungal activity with less toxicity compared to traditional intravenous formulations. The publication is seen as a significant milestone for Matinas' ongoing development efforts in combating invasive fungal infections.
Read more →MTNBMatinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
Matinas BioPharma reported its Q2 2023 financial results and provided updates on its lead asset, MAT2203, an oral antifungal treatment. The FDA indicated stringent requirements for approval, necessitating a study with significant participant numbers. Nonetheless, there are positive signs from compassionate use cases, where MAT2203 has shown effectiveness in critically ill patients. Financially, the company is facing challenges with a reported net loss, but it remains focused on extending its cash runway through partnerships and grants.
Read more →MTNBMatinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
Matinas BioPharma Holdings, Inc. announced its participation in the BTIG Virtual Biotechnology Conference 2023, scheduled for August 7-8, 2023. CEO Jerome D. Jabbour will meet with institutional investors, and the company's presentation is available on its Investor page. Matinas is developing its lead drug, MAT2203, which shows promise in treating invasive fungal infections and has successfully completed Phase 2 trials. The company also emphasizes the potential of its lipid nanocrystal technology for enhanced drug delivery.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
Matinas BioPharma Holdings, Inc. is set to report its second quarter 2023 financial results on August 9, 2023, followed by a conference call to discuss these results and offer a business update. The company's lead therapy, MAT2203, utilizes a lipid nanocrystal platform for effective oral delivery of amphotericin B, which has undergone successful trials against cryptococcal meningitis. Additionally, Matinas is looking to position MAT2203 for a pivotal Phase 3 study addressing various invasive fungal infections. Their technology aims to resolve challenges in drug delivery for both small molecules and larger biologicals.
Read more →MTNB▼ -29.7%on this news
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
Matinas BioPharma will present an overview at the JMP Securities Life Sciences Conference on May 15, 2023. CEO Jerome D. Jabbour is scheduled to discuss the company's innovative lipid nanocrystal (LNC) delivery technology. This technology aims to address challenges in the safe and effective delivery of various therapeutic molecules. Matinas is also developing a new non-LNC nanoparticle delivery system, potentially offering benefits over traditional lipid nanoparticles.
Read more →MTNB▲ +8.1%on this news· ran to -26% by day 3shared move
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
Matinas BioPharma announced its first quarter 2023 financial results and provided updates on its development programs. The FDA expressed encouraging support for MAT2203, an oral treatment for invasive fungal infections (IFIs), stating its intent to collaborate on a Phase 3 trial design. However, the company reported disappointing results from an initial oral mRNA delivery study conducted with BioNTech, leading to the conclusion of their collaboration. Matinas is actively seeking funding from BARDA and ARPA-H to advance MAT2203's development and has seen positive outcomes in compassionate use cases involving patients with challenging infections.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
Matinas BioPharma Holdings, Inc. will announce its first quarter 2023 financial results on May 10, 2023, followed by a conference call for the investment community. The company aims to provide updates on its business and financial performance. Matinas is known for its lipid nanocrystal platform technology, which enhances the delivery of nucleic acids and small molecules. Additionally, the company faces challenges such as securing necessary funding and navigating regulatory approvals.
Read more →MTNB▲ +13.6%on this news· ran to +37% by day 3
Compassionate Use Patient Treated with Matinas BioPharma's MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID BEDMINSTER, N.J. (
Matinas BioPharma (MTNB) has announced the successful treatment of a patient with a rare Rhodotorula mucilaginosa fungal infection using MAT2203, an oral formulation of amphotericin B. The results were presented at ECCMID and indicate complete clinical resolution and no significant renal adverse effects. The company is preparing for a Phase 3 program with the FDA, aiming to evaluate MAT2203's potential to treat invasive fungal infections more broadly. However, it is important to note that MAT2203 is still in the development stage and not yet approved for use.
Read more →MTNBMatinas BioPharma Reports 2022 Financial Results and Provides a Business Update
Matinas BioPharma has reported its 2022 financial results, showcasing a net loss of $21.0 million. The company remains optimistic about advancements in its lipid nanocrystal (LNC) platform and expects significant near-term data readouts, particularly from collaborations with BioNTech and National Resilience. Matinas is seeking FDA guidance for a Phase 3 trial of its oral MAT2203 treatment for invasive fungal infections, anticipating funding from BARDA and NIH to support this initiative. Despite the financial losses, the company believes its technology has strong potential for market approval and continued development.
Read more →MTNBMatinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023
Matinas BioPharma Holdings, Inc. will host a conference call and webcast on March 15, 2023, to discuss its financial results for 2022 and provide a business update. The company is focused on its lipid nanocrystal (LNC) platform technology aimed at improving the delivery of nucleic acids and small molecules. In addition to its proprietary products, Matinas is collaborating with pharmaceutical companies to enhance formulations. However, the company faces several risks including the need for further capital and uncertainties related to clinical testing and regulatory approvals.
Read more →MTNBMatinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
Matinas BioPharma has announced that MAT2203, an oral formulation of amphotericin B, will be featured in two presentations at the upcoming ECCMID conference in April. The presentations will focus on MAT2203's efficacy in treating cryptococcal meningitis and other serious fungal infections. The company emphasizes the advantages of MAT2203's targeted oral delivery, which aims to reduce systemic toxicity compared to traditional intravenous methods. Additionally, Matinas BioPharma expresses optimism about the potential for their lipid nanocrystal technology to enhance drug delivery beyond small molecules.
Read more →MTNBMatinas BioPharma Provides Business Update and 2023 Strategic Outlook
Matinas BioPharma has reported a successful 2022, positioning itself to focus on gene therapies using its lipid nanocrystal delivery platform. The company has established partnerships with BioNTech and National Resilience, which are anticipated to yield critical in vivo data. Matinas is seeking feedback and financial support from BARDA for its MAT2203 Phase 3 study on invasive fungal infections. With approximately $28.8 million in funding, the company plans to extend its operational timeline into Q2 2024 and is pursuing a strategic outlook centered on nucleic acids and gene therapy advancements.
Read more →MTNBMatinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
Matinas BioPharma announced a conference call scheduled for January 30, 2023, to discuss the company's corporate update and business outlook for the upcoming year. Senior management will provide insights on ongoing programs and collaborations. The biopharmaceutical company focuses on innovative intracellular delivery solutions through its lipid nanocrystal (LNC) technology, which could overcome challenges faced by traditional drug delivery systems. The company faces various uncertainties and risks, particularly related to financing and regulatory approvals.
Read more →MTNBMatinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids
Matinas BioPharma has announced a strategic collaboration with National Resilience to explore the oral delivery of nucleic acids using Matinas' lipid nanocrystal (LNC) platform technology. This partnership aims to conduct extensive research, including testing and optimization of nucleic acid formats and their delivery. The LNC platform is positioned to potentially improve intracellular delivery methods beyond traditional approaches, highlighting the commitment to making advanced therapies more accessible. The exact terms of the agreement have not been disclosed.
Read more →MTNBMatinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023 The Infectious Diseases Society o
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022
BEDMINSTER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delive
Read more →MTNB▲ +22.1%on this news
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded the prespecified primary endpoint threshold of >0.20 CFU/mL, CSF/day Favorable safety an
Read more →MTNB▲ +22.1%on this news
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced
Read more →MTNBMatinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delive
Read more →MTNBMatinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that MAT2203 achieves impressive in vivo efficacy and has in vitro killing activity 5 to
Read more →MTNB▲ +6.2%on this news
Matinas BioPharma Announces Chairman Succession Plan
BEDMINSTER, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform deliv
Read more →MTNBMatinas BioPharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announce
Read more →MTNBMatinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility and Clarity on Phase 3 Program and Single Pivotal Registration Trial for MAT2203 in Cryptococcal Meningitis; Trial Expected
Read more →MTNBMatinas BioPharma to Participate in the BTIG Biotechnology Conference
BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022
BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform techno
Read more →MTNB▲ +5.8%on this newsshared move
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis
BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today ann
Read more →MTNBMatinas BioPharma to Present at the LD Micro Invitational XII Conference
BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced
Read more →MTNBMatinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas’ proprietary LNC platform technology – – 50% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data Expected Q3 2022 – – Fe
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022
BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform techno
Read more →MTNBMatinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
BEDMINSTER, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced
Read more →MTNB▲ +23.2%on this news
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines Exclusive collaboration combines BioNTech's mRNA vaccine development expertise and Ma
and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines Exclusive collaboration combines BioNTech's mRNA vaccine development expertise and Matinas' Lipid Nanocrystal (LNC) Delivery Platform Technology to adv
Read more →MTNBMatinas BioPharma to Present at the Needham Virtual Healthcare Conference
BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announc
Read more →MTNB▲ +5.6%on this news· ran to +26% by day 3
Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
BEDMINSTER, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology announce
Read more →MTNB▲ +5.4%on this news
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data to Come from Cohort 5 of EnACT Trial – – Second in vivo Study of Oral LNC-remd
Read more →MTNB▼ -5.1%on this news
Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial and Operational Results on March 8, 2022
BEDMINSTER, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform techn
Read more →MTNB▼ -16.2%on this news
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of EnACT (all oral induction regimen) Underway With Six Patients Enrolled and Toplin
Read more →MTNBMatinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022
BEDMINSTER, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform techn
Read more →MTNBMatinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Data from third patient cohort confirm antifungal activity above pre-defined threshold target for success, while maintaining a desirable overall safety profile – – Enrollment in fourth cohort
Read more →MTNB▲ +7.2%on this news
Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platfo
Read more →MTNBMatinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference
BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platfo
Read more →MTNB▼ -5.6%on this news
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study – – Dosing initiated in Phase 1 stu
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial and Operational Results on November 8, 2021
BEDMINSTER, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delive
Read more →MTNBMatinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series
BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platfo
Read more →MTNBMatinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
BEDMINSTER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platfo
Read more →MTNBMatinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly – BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage bioph
Read more →MTNB▲ +12.4%on this news
Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtua
Read more →MTNB▲ +27.1%on this news· ran to +43% by day 1shared move
Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 – – Overall survival was >95% in 40 patients receiving MAT2203 in Cohort 2 – –
Read more →MTNBMatinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
BEDMINSTER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platfo
Read more →MTNB▼ -5%on this news
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021 – – Positive recent FDA feedback on MAT2501
Read more →MTNBMatinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the BTIG Virtual Biotechnology Conference on Tues
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021
BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delive
Read more →MTNBMatinas BioPharma to Hold Virtual R&D Day on June 17, 2021
Matinas will highlight progress across its lipid nanocrystal (LNC) delivery platform and associated pipeline programs David R. Boulware, M.D., MPH, Professor of Medicine, Infectious Disease and International Medicine, Univ. of Minnesota, and Peter G. Pappas, M.D., Professor of M
Read more →MTNBMatinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
– Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from second cohort anticipated Q3 2021 – – MAT2501 (oral amikacin) advanced into pre
Read more →MTNBMatinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the 7th Annual Truist Securities Life Sciences S
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) deliv
Read more →MTNBMatinas BioPharma to Present at the Needham Healthcare Conference
BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the 20th Annual Needham Virtual Healthcare Conference on Thu
Read more →MTNBMatinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) ev
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021
BEDMINSTER, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today an
Read more →MTNBMatinas BioPharma to Present at the Barclays Global Healthcare Conference
BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the Barclays Global Healthcare Conference on Tuesday, March
Read more →MTNBMatinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa
– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® – – LYPDISO™ demonstrated a 39% relative difference in response over Vascepa in TG reduction – – Primary endpoint of percent change from baseline to end o
Read more →MTNBMatinas BioPharma to Present at the ICR Conference 2021
BEDMINSTER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the ICR Conference 2021 on Thursday, January 14, 2021 at 1:00
Read more →MTNBMatinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
BEDMINSTER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today ann
Read more →MTNBMatinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 - - Company’s Proposal to Stockholders Intended to Enhance Appeal of Common Stock to Institutional Inves
Read more →MTNBMatinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today ann
Read more →MTNBMatinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
BEDMINSTER, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today ann
Read more →MTNBMatinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients
BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today ann
Read more →MTNBMatinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been
Read more →MTNBMatinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights
EnACT study of MAT2203 in cryptococcal meningitis received unanimous Data and Safety Monitoring Board (DSMB) recommendation to proceed into second patient cohort – ENHANCE-IT study of MAT9001 against Vascepa® fully enrolled with topline data anticipated Q1 2021; Phase 3 program
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Third Quarter 2020 Financial and Operational Results on November 6, 2020
BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Friday, November 6, 2020 at 8:30 a.m. ET to d
Read more →MTNBMatinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Enrollment in second cohort of patients expected to commence imminently with next DSMB evaluation anticipated mid-2021 – BEDMINSTER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma H
Read more →MTNBMatinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG)
- FDA Agreement to Move Directly into Phase 3 - - FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG - BEDMINSTER, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage
Read more →MTNBMatinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors
BEDMINSTER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2
Read more →MTNBMatinas BioPharma to Participate on Anti-Fungal CEO Panel During the M-VEST Virtual Conference Series Sponsored by Maxim Group
BEDMINSTER, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate on a panel of top innovators in anti-infective drug development as part of Max
Read more →MTNBMatinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa
BEDMINSTER, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has completed enrollment in the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Effica
Read more →MTNBMatinas BioPharma to Participate in Two Upcoming Virtual Investor Conferences
BEDMINSTER, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview and host one-on-one meetings during two upcoming virtual investo
Read more →MTNBMatinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203
BEDMINSTER, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the publication of data from the Phase 1 portion of the EnACT (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial) study for MAT2203, a novel oral
Read more →MTNBMatinas BioPharma Reports Second Quarter 2020 Financial Results and Operational Highlights
– ENHANCE-IT study of MAT9001 against Vascepa® expected to be fully enrolled in August 2020; topline data anticipated Q1 2021 – – EnACT study of MAT2203 in cryptococcal meningitis resumed enrollment; on track for potential cohort progression Q4 2020 – – Management to host confe
Read more →MTNBMatinas BioPharma to Participate in the BTIG Virtual Biotech Conference 2020
BEDMINSTER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat during the BTIG Virtual Biotech Conference 2020 on Tuesday,
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Second Quarter 2020 Financial and Operational Results on August 10, 2020
BEDMINSTER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Mon
Read more →MTNBMatinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials
- Topline data from ENHANCE-IT study of MAT9001 vs. Vascepa® expected in Q1 2021 - - EnACT remains on track for cohort progression in Q4 2020 - BEDMINSTER, N.J., June 30, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that i
Read more →MTNBMatinas BioPharma to Present at the Jefferies Virtual Healthcare Conference
BEDMINSTER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview during the Jefferies Virtual Healthcare Conference on Tuesday, Ju
Read more →MTNBMatinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights
– ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management to host conference call today, Monday, May 11th, at 4:30 p.m. ET – BEDMINSTER, N.J., May 11, 2020 (GLO
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020
BEDMINSTER, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Mond
Read more →MTNBMatinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference
BEDMINSTER, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a panel discussion, as well as host investor meetings, during the Maxim Gro
Read more →MTNBMatinas BioPharma Provides Comment on Impact of Vascepa Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs
BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa a
Read more →MTNBMatinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis Q1 2020 Management to host conference call today, Monday, March 9th, at 8:00 a.m. ET BEDMINSTER, N.J.,
Read more →MTNBMatinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa
– Topline data expected Q4 2020 – BEDMINSTER, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has initiated the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic A
Read more →MTNBMatinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board
BEDMINSTER, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) today announced the appointment of James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA to its Scientific Advisory Board (SAB). Dr. Underberg is a Clinical Assistant
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020
BEDMINSTER, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Mon
Read more →MTNBMatinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
– Part 2 efficacy portion of EnACT expected to commence Q1 2020 – BEDMINSTER, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has completed it
Read more →MTNBMatinas BioPharma Announces Closing of Public Offering of Common Stock
BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing of its underwritten registered public offering of 32,260,000
Read more →MTNBMatinas BioPharma Announces Pricing of Public Offering of Common Stock
BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 32,260,000 s
Read more →MTNBMatinas BioPharma Announces Proposed Public Offering of Common Stock
BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock.
Read more →MTNBMatinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform
BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group. This feasibility evaluation will involve the development of oral
Read more →MTNBMatinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference
BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview, as well as host inv
Read more →MTNBMatinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
– Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020 – – NIH-funded Phase 2 EnACT trial of MAT2203 in cryptococcal meningitis initiated in October – – Management to hos
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019
BEDMINSTER, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Wednesday, November 13, 2019 at 8:00 a.m. ET to dis
Read more →MTNBMatinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis
BEDMINSTER, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and
Read more →MTNBMatinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis
BEDMINSTER, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MAT2203, Matinas’ proprietar
Read more →MTNBMatinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference
BEDMINSTER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings
Read more →MTNBMatinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa
BEDMINSTER, N.J., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head phar
Read more →MTNBMatinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
BEDMINSTER, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings,
Read more →MTNBMatinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
– MAT9001 program progressing ahead of schedule – – Additional head to head data vs. Vascepa® expected in 2020 – – NIH-funded Phase 1/2 EnACT trial of MAT2203 in cryptococcal meningitis to commence in Q4 2019 – – Management to host conference call today, Tuesday, August 13th,
Read more →MTNBMatinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019
BEDMINSTER, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Tuesday, August 13, 2019 at 8:00 a.m. ET to discuss
Read more →MTNBMatinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
BEDMINSTER, N.J., July 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated MAT2203, Matinas’ proprietary oral amphotericin B pr
Read more →MTNBMatinas BioPharma to Present at the 9th Annual LD Micro Invitational
BEDMINSTER, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present at the 9th Annual LD Micro Invitational
Read more →MTNBMatinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio
– Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – – Cryptococcal meningitis is one of the most frequent and opportunistic infections in Human Immuno-Defic
Read more →MTNBMatinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019
BEDMINSTER, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal (“LNC”) formulation of t
Read more →MTNBMatinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
BEDMINSTER, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that they have entered into a research collaboration with ViiV Healthcare, a global specialist HIV company established in November of 2009 by GlaxoSmithKline (LS
Read more →MTNBMatinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results
BEDMINSTER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2019 and provided an update on its corporate activities and pro
Read more →MTNBMatinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019
BEDMINSTER, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 14, 2019 at 8:30 a.m. ET to discu
Read more →MTNBMatinas BioPharma to Ring NYSE Opening Bell on May 6, 2019
BEDMINSTER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to ring the NYSE Opening Bell® on Monday, May 6th, 2019 at 9:30 AM E.T., to commemorate a tr
Read more →MTNBMatinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference
BEDMINSTER, N.J., May 01, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D., Chief Development Officer of the Company, was selected to present a corporate overview
Read more →MTNBMatinas BioPharma Reports 2018 Financial Results and Provides Corporate Update
– Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3 market – – Company continues to drive development of proprietary and highly differentiated lipi
Read more →MTNBMatinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019
BEDMINSTER, N.J., March 26, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, April 2, 2019 at 8:00 a.m. ET to di
Read more →MTNBMatinas BioPharma Announces Proposed Public Offering of Common Stock BEDMINSTER, N.J.
BioPharma Announces Proposed Public Offering of Common Stock BEDMINSTER, N.J., March 14, 2019 (BUSINESS WIRE) Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") - (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has com
Read more →MTNBProminent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer - Former Head of U.S. Cardiovascular Medical Affairs at Amgen and Global Cardiovascular Medical Affair
Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer Former Head of U.S. Cardiovascular Medical Affairs at Amgen and Global Cardiovascular Medical Affairs at AstraZeneca to lead clinical development of MAT9001, a potential
Read more →MTNBMatinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform
BEDMINSTER, N.J., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic ef
Read more →MTNBMatinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer
BEDMINSTER, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed Keith A. Kucinski, CPA, MBA as Chief Financial Officer. Mr. Kucinski brings to Matinas over 20
Read more →MTNBMatinas BioPharma to Present at Biotech Showcase 2019
– Presentation with live audio webcast Monday, January 7th at 3:30 PM PST – BEDMINSTER, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive
Read more →MTNBMatinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board
BEDMINSTER, N.J., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced the appointment of Harold E. Bays, M.D. to its Scientific Advisory Board (SAB). Dr. Bays is Board Certified in Endoc
Read more →MTNBMatinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001
BEDMINSTER, N.J., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has established a new Scientific Advisory Board to guide the development of its proprietary, prescription-
Read more →MTNBMatinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update
– Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3 drug class – – Company continues to drive development of proprietary and highly di
Read more →MTNBMatinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033
BEDMINSTER, N.J., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic
Read more →MTNBMatinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference
BEDMINSTER, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that Raphael Mannino, Ph.D., Chief Scientific Officer of Matinas, will present at the 8th Annual Partnership Opportu
Read more →MTNBMatinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
- Dr. Matkovits is an industry leader with 20+ years of proven global drug development success bringing 4 approved medicines to several global markets - - Frank Calamusa, CSCP, an established biotech CMC leader with 20+ years of experience, appointed Executive Director, Head of
Read more →MTNBMatinas BioPharma to Present at the MicroCap Conference
BEDMINSTER, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platfo
Read more →MTNBMatinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors
BEDMINSTER, N.J., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platfor
Read more →MTNBMatinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
BEDMINSTER, N.J., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platfo
Read more →MTNBMatinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop
BEDMINSTER, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platfor
Read more →MTNBMatinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update
– Management intently focused on advancing proprietary and highly differentiated lipid nano-crystal platform delivery technology – – Multiple discussions with strategic partners remain ongoing – – Lead platform-validating asset, MAT2203, positioned for streamlined development
Read more →MTNBMatinas BioPharma Announces Closing of $8.0 Million Public Offering
BEDMINSTER, N.J., June 22, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today
Read more →MTNBMatinas BioPharma Announces Pricing of $8.0 Million Public Offering
BEDMINSTER, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today
Read more →MTNBMatinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host
BEDMINSTER, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today
Read more →MTNBMatinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform
BEDMINSTER, N.J., June 06, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today
Read more →MTNBMatinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update
– Management to host conference call with live audio webcast today, Thursday, May 10th at 8:30 am EDT – BEDMINSTER, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delive
Read more →MTNBMatinas BioPharma to Host Quarterly Update Conference Call
BEDMINSTER, N.J., May 07, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (“LNC”) platform delivery technolog
Read more →MTNBMatinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference
BEDMINSTER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative medicines using its proprietary lipid nano-crystal (“LNC”) platform delivery technology, today announc
Read more →MTNBMatinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease
BEDMINSTER, N.J., April 19, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that it will present a poster at the 28th Eu
Read more →MTNBMatinas BioPharma Reports 2017 Financial Results
BEDMINSTER, N.J., March 26, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today formally announced its financial results for the year
Read more →MTNBMatinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update
Leadership appointment positions Company for next stage of value creation Successful outcome of meeting with FDA provided important insight and clarity for clinical development path forward for MAT2203 Conference call and live audio webcast to be held on March 19th at 8:30 a.m.
Read more →MTNBMatinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference
BEDMINSTER, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that Co-Founder and President, Jerome D. Jabb
Read more →MTNBMatinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast
BEDMINSTER, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that it will host a 2017 financial results an
Read more →MTNBMatinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
–100% (three out of three) of patients have now met the primary endpoint in achieving ≥ 50% clinical response with MAT2203 – – Study has met predetermined statistical endpoint for success – – All patients have elected to continue treatment in open-label extension study, with tw
Read more →MTNBMatinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors
BEDMINSTER, N.J., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced the appointment of Matthew A. Wikler, M.D., M.B.A.,
Read more →MTNBMatinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update
BEDMINSTER, N.J., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced its financial results for the quarter ended Se
Read more →MTNBMatinas BioPharma to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
BEDMINSTER, N.J., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour, Co-Founder and Preside
Read more →MTNBMatinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference
BEDMINSTER, N.J., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour, Co-Founder and Presid
Read more →MTNBMatinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001
– MAT9001 is a uniquely engineered omega-3 fatty acid comprising docosapentaenoic acid (DPA) for the treatment of hypertriglyceridemia – – MAT9001 demonstrated superiority versus Amarin’s Vascepa® on bioavailability, triglyceride reduction and other lipid endpoints – BEDMINSTER
Read more →MTNBMatinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
Second quarter marked by significant clinical progress with compelling overall Phase 2 data from two studies of flagship product candidate MAT2203 Company plans to engage FDA to review overall data package generated with MAT2203 with the goal to enter Phase 3 for the prevention
Read more →MTNBwww.matinasbiopharma.com NYSE MKT: MTNB Canaccord Genuity 37 th Annual Growth Conference Jerrome D. Jabbour, Co - founder and President Forward Looking Statement This presentation contains "forward - looking statements"
www.matinasbiopharma.com NYSE MKT: MTNB Canaccord Genuity 37 th Annual Growth Conference Jerrome D. Jabbour, Co - founder and President Forward Looking Statement This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Ref
Read more →MTNBMatinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference
- Presentation with live audio webcast on Thursday, August 10th at 11:00 AM EDT - BEDMINSTER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for
Read more →MTNBMatinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
BEDMINSTER, N.J., June 26, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today reported topline data from its Phase 2 safety, tolerabil
Read more →MTNBMatinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
– NIH investigators present collaborative interim data of MAT2203 study at The American Society for Microbiology’s ASM Microbe 2017 Conference – – Two out of two patients met the primary endpoint in achieving ≥ 50% clinical response with MAT2203 – – MAT2203 was well tolerated w
Read more →MTNBMatinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
BEDMINSTER, N.J., June 02, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced the presentation of preclinical efficacy data
Read more →MTNBMatinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference
BEDMINSTER, N.J., June 01, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour, Co-Founder and President
Read more →MTNBMatinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J. Mannino, to present preclinical data of MAT2203 in Cryptococcal Me
Read more →MTNBMatinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update
– Announced positive topline data from initial study in Phase 1 program for MAT2501 – – Company on track to report interim Phase 2 data of MAT2203 for mucocutaneous candidiasis and topline data of MAT2203 Phase 2 study for vulvovaginal candidiasis in June 2017 – BEDMINSTER, N.J
Read more →MTNBMatinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases
BEDMINSTER, N.J., April 24, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that it presented positive preclinical data a
Read more →MTNBMatinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
BEDMINSTER, N.J., April 18, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that it has appointed Dominick DiPaolo as Sen
Read more →MTNBBioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance Bedminster, NJ (April 18, 2017) - Matinas BioPharma Holdings, Inc. (NYSE MKT: MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives fo
Read more →MTNBMatinas BioPharma Reports 2016 Financial Results and Provides Corporate Update
– 2016 marked by significant corporate and clinical advancements – – Recently announced positive topline data from initial study in Phase 1 program for MAT2501 – – On track to report interim Phase 2 data of MAT2203 and topline data of MAT2203 VVC study in June 2017 – – Confere
Read more →MTNBMatinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors
BEDMINSTER, N.J., March 30, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today the appointment of Eric J. Ende, M.B.A, M.D.,
Read more →MTNBMatinas BioPharma to Host Fiscal Year 2016 Update Conference Call
BEDMINSTER, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that it will report its financial results for
Read more →MTNBMatinas BioPharma to Ring NYSE Closing Bell on March 29th, 2017
BEDMINSTER, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that Roelof Rongen, Co-Founder and Chief Exec
Read more →MTNBMatinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501
- Oral administration of MAT2501 at all tested doses yielded blood levels that were well below the labeled safety limits recommended for IV-administered amikacin - - MAT2501 was well-tolerated with no serious adverse events observed - BEDMINSTER, N.J., March 27, 2017 (GLOBE NEW
Read more →MTNBMatinas BioPharma to Present at 29th Annual ROTH Conference
BEDMINSTER, N.J., March 10, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that Jerome D. Jabbour, Co-Founder and Presiden
Read more →MTNBMatinas BioPharma Announces Positive Preclinical Efficacy Results of MAT2501 in an In Vitro Model of Mycobacterium abscessus Infection
BEDMINSTER, N.J., March 08, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced positive efficacy results from the study of M
Read more →MTNBMatinas BioPharma and NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in Chronic Mucocutaneous Candidiasis
– Matinas BioPharma to commence 6-month safety open-label extension to Phase 2a study with National Institutes of Health (NIH) – – On track to report Phase 2a topline data for MAT2203 in 2Q 2017 – BEDMINSTER, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings,
Read more →MTNBMatinas BioPharma Announces Trading on NYSE MKT to Commence March 2, 2017
BEDMINSTER, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that its common stock has been approved for listi
Read more →MTNBMatinas BioPharma Provides Business Outlook and Sets Corporate Milestones for 2017
-- Several data milestones anticipated during 1H 2017 -- Recent warrant tender offer resulting in $13.5 million in gross proceeds strengthens balance sheet and extends cash runway into 2Q 2018 -- New GLP/cGMP manufacturing facility positions Company for expected pivotal program
Read more →MTNBMatinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
BEDMINSTER, N.J., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour, Co-founder and President
Read more →MTNBMatinas BioPharma Successfully Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants
BEDMINSTER, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today the successful completion of its tender offer to
Read more →MTNBMatinas BioPharma to Present at Biotech Showcase™ 2017
BEDMINSTER, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour, Co-Founder and President, w
Read more →MTNBMatinas BioPharma Receives Contract Award from Cystic Fibrosis Foundation Therapeutics to Study MAT2501 for the Treatment of NTM-Infection in Pre-Clinical Models of CF
BEDMINSTER, N.J., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBMatinas BioPharma Commences Dosing in Phase 1 Study of Orally Administered Aminoglycoside Antibiotic MAT2501
– MAT2501 previously received Orphan Drug and Qualified Infectious Disease Product designations for treatment of nontuberculous mycobacterium infections by U.S. FDA – – Phase 1 data expected in the first half of 2017 – BEDMINSTER, N.J., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Matinas
Read more →MTNBMatinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis
- Second Phase 2 study of lead anti-infective candidate MAT2203 - – On track to report Phase 2 topline data for MAT2203 in the first half of 2017 – BEDMINSTER, N.J., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceuti
Read more →MTNBMatinas BioPharma Reports 2016 Third Quarter Financial Results and Provides Corporate Update
– Company to commence initial study in the Phase 1 program for MAT2501 and second Phase 2 study for MAT2203 in Q4 2016 – – On track to report Phase 2 topline data for MAT2203 in the first half of 2017 – BEDMINSTER, N.J., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdi
Read more →MTNBMatinas BioPharma Researchers Among Rutgers University Recipients of 2016 Edison Patent Awards
BEDMINSTER, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBMatinas BioPharma Presents Preclinical Data of Orally Administered Encochleated Influenza Vaccine in Murine Model at IDWeek 2016
BEDMINSTER, N.J., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBMatinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
BEDMINSTER, N.J., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBMatinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference
BEDMINSTER, N.J., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBwww.matinasbiopharma.com OTCQB: MTNB TRANSFORMING THE WAY POTENT MEDICINES FOR INFECTIOUS DISEASES ARE DESIGNED MAT2203 CLINICAL DEVELOPMENT UPDATE CALL OCTOBER 6, 2016 Forward Looking Statement This presentation contain
www.matinasbiopharma.com OTCQB: MTNB TRANSFORMING THE WAY POTENT MEDICINES FOR INFECTIOUS DISEASES ARE DESIGNED MAT2203 CLINICAL DEVELOPMENT UPDATE CALL OCTOBER 6, 2016 Forward Looking Statement This presentation contains "forward - looking statements" within the meaning of the
Read more →MTNBMatinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203
– Phase 2a study of MAT2203 for the treatment of mucocutaneous candidiasis infections; Topline data expected in H1 2017 – Management to host conference call and webcast on October 6th at 4:30 p.m. ET to review clinical development strategy for MAT2203 BEDMINSTER, N.J., Sept. 28
Read more →MTNBMatinas BioPharma Completes Private Placement of $8.0 Million
BEDMINSTER, N.J., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treat
Read more →MTNBMatinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
- Third QIDP Designation Granted by FDA for MAT2203 – - Phase 2a study enrollment underway to evaluate MAT2203 for the treatment of chronic mucocutaneous candidiasis at NIH/NIAID - BEDMINSTER, N.J., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB
Read more →MTNBMatinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016
BEDMINSTER, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening in
Read more →MTNBMatinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016
BEDMINSTER, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBMatinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
BEDMINSTER, N.J., June 22, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBMatinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
BEDMINSTER, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening inf
Read more →MTNBMatinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
- Study demonstrates higher potency and better safety/tolerability of ibuprofen in lipid-crystal nano-particle formulation - - EULAR Scientific Congress being held June 8-11, 2016 - BEDMINSTER, N.J., June 08, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB
Read more →MTNBMatinas BioPharma Reports 2015 Financial Results and Provides Business Update
2015 transformative year with focus on developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections 2016 expected to produce confirmatory data for cochleate technology platform Topline data from Phase 2a clinical trial w
Read more →MTNBMatinas BioPharma to Present at the 28th Annual ROTH Conference
BEDMINSTER, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, annou
Read more →MTNBMatinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections
- MAT2501 (encochleated amikacin) previously designated a Qualified Infectious Disease Product by FDA - - MAT2501 demonstrated oral bioavailability and targeted delivery directly to site of non-tuberculous mycobacteria (NTM) infections in preclinical studies - - Phase 1 program
Read more →MTNBMatinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B
- First Dosing of Patients Expected in 1Q 2016 - - Topline Data From Phase 2a Clinical Trial With MAT2203 for the Treatment of Refractory Mucocutaneous Candidiasis Expected in 2016 - BEDMINSTER, N.J., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTN
Read more →MTNBMatinas BioPharma Receives FDA Clearance to Initiate Phase 1 Clinical Study of MAT2501 for the Treatment of Non-Tuberculous Mycobacterium Infections
BEDMINSTER, N.J., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today
Read more →MTNBMatinas BioPharma to Present at Biotech Showcase™ on January 12, 2016
BEDMINSTER, N.J., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announ
Read more →MTNBMatinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
BEDMINSTER, N.J., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announ
Read more →MTNBMatinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
BEDMINSTER, N.J., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today
Read more →MTNBMatinas BioPharma’s Lead Antibacterial Development Candidate MAT2501 Granted QIDP Designation by U.S. FDA
BEDMINSTER, N.J., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today
Read more →MTNBMatinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
BEDMINSTER, N.J., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today
Read more →MTNBMatinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
- Topline data from Phase 2a clinical trial with MAT2203, oral encochleated amphotericin B, expected in 2016 - - IND for MAT2501, oral encochleated amikacin, expected to be submitted in 4Q’15 - BEDMINSTER, N.J., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc.
Read more →MTNBMatinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
BEDMINSTER, N.J., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today
Read more →MTNBMatinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
BEDMINSTER, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today
Read more →MTNBMatinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
BEDMINSTER, N.J., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today
Read more →MTNBMatinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
- CATQ – Encochleated Atovaquone – Demonstrates Enhanced Efficacy and Tissue Targeting over Current Formulation - BEDMINSTER, N.J., Oct. 10, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying
Read more →MTNBMatinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 – An Orally Delivered, Encochleated Formulation of Amphotericin B –
- NIH IRB Approves Study of MAT2203 - Oral, Encochleated Formulation of Amphotericin B - - Phase 2a Top line data expected in 2016 - BEDMINSTER, N.J., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company foc
Read more →MTNBMatinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
BEDMINSTER, N.J., Sept. 19, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life
Read more →MTNBMatinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
BEDMINSTER, N.J., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life
Read more →MTNBMatinas BioPharma Appoints International Expert and Thought Leader on Invasive Fungal Infections Peter G. Pappas, M.D., FACP, to Scientific Advisory Board
BEDMINSTER, N.J., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life
Read more →MTNBwww.matinasbiopharma.com OTCQB: MTNB TRANSFORMING THE WAY POTENT MEDICINES FOR INFECTIOUS DISEASES ARE DESIGNED Corporate Presentation September 2015 Forward Looking Statement This presentation contains "forward - lookin
www.matinasbiopharma.com OTCQB: MTNB TRANSFORMING THE WAY POTENT MEDICINES FOR INFECTIOUS DISEASES ARE DESIGNED Corporate Presentation September 2015 Forward Looking Statement This presentation contains "forward - looking statements" within the meaning of the Private Securities
Read more →MTNBMatinas BioPharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 9, 2015
BEDMINSTER, N.J., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-
Read more →MTNBMatinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
BEDMINSTER, N.J., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB: MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life
Read more →MTNBMatinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA
BEDMINSTER, N.J., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-
Read more →MTNBMatinas BioPharma Announces Abstract on Pharmacokinetics and Efficacy of Encochleated Atovaquone in Murine Model of Pneumocystis Accepted for Oral Presentation at IDWeek 2015
BEDMINSTER, N.J., July 27, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-
Read more →MTNBMatinas BioPharma Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
BEDMINSTER, N.J., July 23, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-
Read more →MTNBMatinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015
Data demonstrating rapid tissue penetration in animal studies of oral encochleated Amphotericin B in systemic candidiasis to be presented on Sept. 18 Results of oral encochleated Amikacin in mycobacterium avium in vivo (lung biofilm) and in vitro (biofilm) models to be presented
Read more →MTNBMatinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
BEDMINSTER, N.J., July 7, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the 12th Anti-Infectives Partnering and Deal Making C
Read more →MTNBMatinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
BEDMINSTER, N.J., June 15, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, announced the presentation of data from a head-to-head study that showed MAT9001, a prescription-only omega-3 fatty acid-based compositio
Read more →MTNBMatinas BioPharma to Present at the BIO International Convention on June 18, 2015
BEDMINSTER, N.J., June 10, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the BIO International Convention being held June 15-
Read more →MTNBMatinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
BEDMINSTER, N.J., June 4, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting additional data from the MAT9001 head-to-head comparativ
Read more →MTNBMatinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
- MAT9001 demonstrates superiority versus Vascepa on bioavailability, triglyceride reduction and other lipid endpoints - - MAT9001 is the first orally-administered dyslipidemia product reported to significantly reduce PCSK9 in patients - BEDMINSTER, N.J., June 1, 2015 (GLOBE NE
Read more →MTNBMatinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
BEDMINSTER, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious dise
Read more →MTNBMatinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
BEDMINSTER, N.J., May 26, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of
Read more →MTNBMatinas BioPharma Completes Private Placement of $10 Million
BEDMINSTER, N.J., April 10, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the
Read more →MTNBMatinas BioPharma to Present at the 2nd Annual Growth Capital Expo on April 13, 2015
BEDMINSTER, N.J., April 7, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the t
Read more →MTNBMatinas BioPharma Completes Enrollment in First Human Trial of MAT9001
- Study Steering Committee Recommends Early Completion of Enrollment Due to Adequate Power in Study to Demonstrate Study Endpoints - - Top-line Data Expected to be Reported in Second Quarter 2015 - BEDMINSTER, N.J., March 30, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings,
Read more →MTNBUnaudited Pro Forma Condensed Combined Financial Statements of Matinas BioPharma Holdings Inc. The following unaudited pro forma condensed combined financial information has been prepared to reflect adjustments to the fi
Unaudited Pro Forma Condensed Combined Financial Statements of Matinas BioPharma Holdings Inc. The following unaudited pro forma condensed combined financial information has been prepared to reflect adjustments to the financial condition and results of operations of Matinas Bi
Read more →MTNBMatinas BioPharma to Present at the 27th Annual ROTH Conference on March 11, 2015
BEDMINSTER, N.J., March 4, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (Matinas BioPharma or the Company) (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treat
Read more →MTNBMatinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
BEDMINSTER, N.J., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the tr
Read more →MTNBMatinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, with Acquisition of Aquarius BioTechnologies Inc. - Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad
Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, with Acquisition of Aquarius BioTechnologies Inc. Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad use in anti-infectives featuring targeted delivery and mul
Read more →MTNBMatinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
- Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad use in anti-infectives featuring targeted delivery and multi-organ protection - - Lead program for oral administration of Amphotericin B antifungal (MAT2203) with positive safe
Read more →MTNBMatinas BioPharma to Present at the Biotech Showcase 2015 Conference on January 14, 2015
BEDMINSTER, N.J., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics fo
Read more →MTNBMatinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
BEDMINSTER, N.J., Dec. 23, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBMatinas BioPharma Receives FDA Feedback on IND Submission and Provides Update on Clinical Development Program for MAT9001 BEDMINSTER, NJ (
Matinas BioPharma Receives FDA Feedback on IND Submission and Provides Update on Clinical Development Program for MAT9001 BEDMINSTER, NJ (December 23, 2014) - Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB: MTNB), an emerging biopharmaceutical
Read more →MTNBMatinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
BEDMINSTER, N.J., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBMatinas BioPharma to Present at Two Investor Conferences in Early December
- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST - - RetailInvestorConferences.com Live and Interactive Online Presentation on Thursday, December 4, 2014, at 12:00 p.m. PST / 3:00 p.m. EST - BEDMINSTE
Read more →MTNBMatinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
BEDMINSTER, N.J., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBMatinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001
BEDMINSTER, N.J., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBMatinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
BEDMINSTER, N.J., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics fo
Read more →MTNBMatinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
BEDMINSTER, N.J., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBMatinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
BEDMINSTER, N.J., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBMatinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014
BEDMINSTER, N.J., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics
Read more →MTNBMatinas BioPharma Holdings, Inc. Approved to Trade on OTCQB Venture Stage Marketplace
BEDMINSTER, N.J., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBMatinas BioPharma to Present at Three Investor Conferences in September
- Rodman & Renshaw 16th Annual Global Investment Presentation and Live Audio Webcast on September 9, 2014 - - SeeThruEquity Fall Microcap Presentation on September 11, 2014 - - Aegis Capital 2014 Healthcare and Technology Presentation and Live Audio Webcast on September 12, 201
Read more →MTNBCorporate Presentation Forward Looking Statement This presentation contains "forward - looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Compa
Corporate Presentation Forward Looking Statement This presentation contains "forward - looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines
Read more →MTNBMatinas BioPharma Launches Digital Corporate Communication Channels
BEDMINSTER, N.J., July 31, 2014 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCBB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics f
Read more →MTNBSLIDE PRESENTATION Corporate Presentation Forward Looking Statement This presentation contains "forward - looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those re
Corporate Presentation Forward Looking Statement This presentation contains "forward - looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines
Read more →Competitive Position
How MTNB ranks across every disease it competes inCompetitive Position is a premium feature
See how MTNB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial